Objectives
We investigated the incidence and potential underlying risk factors of venous thromboembolism (VTE) in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We assessed haemostatic disturbances and factors that may contribute to the risk of VTE development.
Methods
ANCA-positive AAV patients (n = 187) were included. Previously identified risk factors for VTE and current medication were retrieved from medical records. We assessed haemostasis using different methods: endogenous thrombin potential (ETP), overall haemostatic potential (OHP), overall coagulation potential (OCP) and overall fibrinolysis potential (OFP) in patients with active AAV (n = 19), inactive AAV (n = 15) and healthy controls (n = 15).
Results
Twenty-eight VTEs occurred in 24 patients over a total follow-up time of 1020 person-years. A majority of VTEs occurred within the first year after diagnosis. High age (p < 0.01), ongoing prednisolone treatment and recent rituximab administration were more common in the VTE group (p < 0.05 for all).
ETP and OHP were significantly increased and OFP significantly decreased in plasma from active compared with inactive AAV-patients (p < 0.05, p < 0.01 and p < 0.05, respectively) and healthy controls (p < 0.001). We could not confirm previously reported risk factors for VTE development.
Conclusions
A high prevalence of VTE in AAV-patients was seen within the first year after diagnosis, suggesting that disease activity contribute to VTE development. High age and concurrent treatment should also be taken in account when estimating VTE risk. The results also indicate disturbances in the haemostatic balance towards pro-thrombotic condition in AAV patients, where ETP and OHP may be useful markers for identifying patients at high risk.